Skip to main content
German Center for Infection Research
  • Research
    • Back
    • Bridging Topics
    • Research Areas
    • Infrastructures
    • Working Groups
    • Projects
    • African Partner Institutions
    • Clinical Trials
    • Publications
  • Translation
    • Back
    • Developing Medication
    • Successful Translation
    • Collaborations
    • German Centers for Health Research
  • DZIF Academy
  • Newsroom
    • Back
    • News
    • Media Centre
    • Press Office
    • Events
    • Jobs
  • About us
    • Back
    • Portrait
    • DZIF Structure and Bodies
    • Partner Sites
    • Executive Board
    • DZIF Patient Advisory Board
    • Staff
    • Main Office
    • Donations
  • De
  • |
  • En

Search

Breadcrumb

  1. Home
  2. Search
Dec 2022
RMD open

Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease

Autoren
Frommert LM et al.
Oct 2022
J Clin Invest

Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

Autoren
Meyer Zu Natrup C et al.
Nov 2022
Infection

Vaccine-hesitant individuals accumulate additional COVID-19 risk due to divergent perception and behaviors related to SARS-CoV-2 testing: a population-based, cross-sectional study

Autoren
Wratil PR et al.
Nov 2022
Sci Immunol

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice

Autoren
Muik A et al.
Sep 2022
Clin Kidney J

Increasing but insufficient neutralizing activity against Omicron-BA.1 after a second booster dose of mRNA-1273 vaccine in chronic haemodialysis patients

Autoren
Ovcar E et al.
Nov 2022
Lancet Infect Dis

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages

Autoren
Arora P et al.
Nov 2022
Hemasphere

Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Autoren
Salmanton-García J et al.
Andreas Dräger and his team

Please use this image only in connection with this press release.

© Uni Tübingen

© Uni Tübingen
Mar 24 2023

Preparing for the next pandemic: Targeted computer modelling to accelerate antiviral drug development

Effective drugs against viral diseases like COVID-19 are urgently needed now and in the future. The emergence of viral mutants and yet unknown viruses could push vaccines to their limits. The DZIF

Klaus Schwamborn

Please use this image only in connection with this interview.

© HZI/Foto: Stefanie Lohde

© HZI/Foto: Stefanie Lohde
Mar 2 2023

„To translate Science into Product Candidates! “

In October 2022, Dr Klaus Schwamborn took over as Head of Vaccine Development in the Translational Project Management Office (TPMO) at DZIF. The TPMO supports product development, from active

Heidelberg University Hospital

Nucleoside Booster Project: Broad-spectrum antivirals for pandemic preparedness

The SARS-CoV-2 pandemic and other epidemics in recent decades have highlighted the need to develop effective measures to combat emerging infectious diseases in a timely manner. For most emerging viral pathogens, no vaccines or antiviral drugs are yet available. Since it is difficult to predict which ...

Pagination

Previous page ‹‹
Seite 11 Seite 12 Seite 13 Seite 14 Current page 15 Seite 16 Seite 17 Seite 18 Seite 19
Next page ››

Sitemap

  • Research
  • Translation
  • DZIF Academy
  • Newsroom
  • About us

At one click

  • Jobs
  • Media Centre
  • Press releases
  • Press contact
  • Glossary
  • Donations

Newsletter Subscription

Contact

Main Office of the DZIF e. V.
Inhoffenstraße 7
38124 Braunschweig
​

E-Mail Send mail

Fußbereichsmenü

  • DZIF Portal (internal)
  • Whistleblower system
  • Imprint
  • Privacy policy
  • Log in
  • Manage cookie consent
German Centers for Health Research
Supported by the Federal Ministry of Research, Technology and Space and the participating federal states